EUVIMEDEUVIMED entdecken
BeobachtungsstudieKohortenstudie

Structured management of dopamine agonist withdrawal in restless legs syndrome with augmentation: A prospective real-world cohort study

Raquel Martín García, Sara Boi, Celia Garcia-Malo

Sleep Medicine · 2026-12 · 148 · 109238

DOI: 10.1016/j.sleep.2026.109238 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Sleep Medicine, 2026-12. Verfasst von Raquel Martín García und 2 weiteren Autor:innen. Beteiligte Einrichtung: Sleep and Neuroscience Center CISNe, Madrid, Spain; Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; Escuela de Doctorado, Univers…. Hauptthemen laut MEDLINE: Restless Legs Syndrome, Dopamine Agonists, Aripiprazole, Substance Withdrawal Syndrome. Die Arbeit nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Augmentation is a major complication of dopamine agonist (DA) therapy for restless legs syndrome (RLS) and its management continues to be a major clinical challenge. We sought to evaluate the feasibility and efficacy of a structured protocol designed to achieve complete DA withdrawal within one month. METHODS: In this prospective observational cohort at a specialized sleep center, consecutive adults with RLS and clinically significant augmentation treated with DA therapy underwent a structured withdrawal protocol that included rapid DA tapering, iron optimization, and alpha-2-delta ligand initiation or increase, with the dopamine partial agonist, aripiprazole, considered as an adjunctive option in patients with significant worsening. RESULTS: Of 31 patients, 24 (77%) achieved complete DA withdrawal at one month. Mean International RLS score improved from 27.1 to 15.1 and Clinical Global Impressions Severity from 5.2 to 3.5 (both p < 0.001), while gabapentin-equivalent dose increased from 417 to 1288 mg/day. Longer augmentation duration was associated with failure to withdraw (11.4 vs. 3.5 years; p = 0.003). Aripiprazole use during tapering was associated with successful withdrawal. CONCLUSIONS: A structured protocol achieved complete DA withdrawal in the majority of patients within one month, with short-term clinical improvement. Early management of augmentation improves the likelihood of successful withdrawal.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Restless Legs SyndromeDopamine AgonistsAripiprazoleSubstance Withdrawal SyndromeHumansProspective StudiesFemaleMaleMiddle AgedGabapentinAminesCyclohexanecarboxylic Acidsgamma-Aminobutyric AcidAdultCohort StudiesTreatment Outcome

Stichwörter der Autor:innen

AripiprazoleAugmentationProtocolRestless legs syndromeWithdrawal

Substanzen

Dopamine AgonistsAripiprazoleGabapentinAminesCyclohexanecarboxylic Acidsgamma-Aminobutyric Acid

Autor:innen und Institutionen

  • Sleep and Neuroscience Center CISNe, Madrid, Spain; Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; Escuela de Doctorado, Universidad Autónoma de Madrid, Madrid, Spain. Electronic address: raquel.mar…
  • Sleep and Neuroscience Center CISNe, Madrid, Spain.

Zitieren

APA

Martín García, R., Boi, S., & Garcia-Malo, C. (2026). Structured management of dopamine agonist withdrawal in restless legs syndrome with augmentation: A prospective real-world cohort study. Sleep Medicine, 148, 109238. https://doi.org/10.1016/j.sleep.2026.109238

Vancouver

Martín García R, Boi S, Garcia-Malo C. Structured management of dopamine agonist withdrawal in restless legs syndrome with augmentation: A prospective real-world cohort study. Sleep Medicine. 2026;148:109238. doi:10.1016/j.sleep.2026.109238

BibTeX
@article{MartnGarca2026,
  author = {Martín García, Raquel and Boi, Sara and Garcia-Malo, Celia},
  title = {Structured management of dopamine agonist withdrawal in restless legs syndrome with augmentation: A prospective real-world cohort study},
  journal = {Sleep Medicine},
  year = {2026},
  volume = {148},
  pages = {109238},
  doi = {10.1016/j.sleep.2026.109238}
}
Kostenlos starten →